Imugene Ltd has released a press release.
Phase 1 CF33-hNIS Study Update - Positive Early Signals
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene and NeoImmuneTech to Improve Cancer Treatments
- Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial
- New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS
- Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine
- Imugene thrilled as VAXINIA granted FDA Fast Track designation
Later from Imugene
- VAXINIA Phase 1 trial doses patients in higher dose cohorts
- Phase 1 onCARlytics Trial Doses First Intravenous Patient
- Phase 1 onCARlytics Trial Advances to Combination Arm
- Imugene to present at 2024 Cholangiocarcinoma Conference
- Oncolytic Virotherapy CF33 Patent Granted in China
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene